JP2011510014A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510014A5
JP2011510014A5 JP2010543237A JP2010543237A JP2011510014A5 JP 2011510014 A5 JP2011510014 A5 JP 2011510014A5 JP 2010543237 A JP2010543237 A JP 2010543237A JP 2010543237 A JP2010543237 A JP 2010543237A JP 2011510014 A5 JP2011510014 A5 JP 2011510014A5
Authority
JP
Japan
Prior art keywords
group
disease
alkyl
carbonyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010543237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510014A (ja
JP5551613B2 (ja
Filing date
Publication date
Priority claimed from US12/009,326 external-priority patent/US8455514B2/en
Application filed filed Critical
Publication of JP2011510014A publication Critical patent/JP2011510014A/ja
Publication of JP2011510014A5 publication Critical patent/JP2011510014A5/ja
Application granted granted Critical
Publication of JP5551613B2 publication Critical patent/JP5551613B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010543237A 2008-01-17 2009-01-15 ６−アミノイソキノリン化合物および７−アミノイソキノリン化合物、ならびにそれらの製造方法および使用方法 Expired - Fee Related JP5551613B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/009,326 2008-01-17
US12/009,326 US8455514B2 (en) 2008-01-17 2008-01-17 6-and 7-amino isoquinoline compounds and methods for making and using the same
PCT/US2009/031117 WO2009091898A2 (en) 2008-01-17 2009-01-15 6-and 7-amino isoquinoline compounds and methods for making and using the same

Publications (3)

Publication Number Publication Date
JP2011510014A JP2011510014A (ja) 2011-03-31
JP2011510014A5 true JP2011510014A5 (enExample) 2012-03-01
JP5551613B2 JP5551613B2 (ja) 2014-07-16

Family

ID=40433990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543237A Expired - Fee Related JP5551613B2 (ja) 2008-01-17 2009-01-15 ６−アミノイソキノリン化合物および７−アミノイソキノリン化合物、ならびにそれらの製造方法および使用方法

Country Status (7)

Country Link
US (2) US8455514B2 (enExample)
EP (4) EP2546237A1 (enExample)
JP (1) JP5551613B2 (enExample)
AU (1) AU2009206075B2 (enExample)
CA (2) CA2712443C (enExample)
ES (3) ES2397928T3 (enExample)
WO (1) WO2009091898A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
BR112013015604B1 (pt) 2010-12-22 2021-11-03 D. Western Therapeutics Institute, Inc Derivado de isoquinolina-6-sulfonamida, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou prevenir glaucoma, hipertensão ocular ou doença cardiovascular
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017184343A1 (en) 2016-04-20 2017-10-26 Hubbell Incorporated Electrical clamps
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN110337292A (zh) 2017-02-28 2019-10-15 兴和株式会社 医药品
EP3590514A4 (en) 2017-02-28 2021-01-06 Kowa Company, Ltd. MEDICAL PREPARATION
WO2018159701A1 (ja) 2017-02-28 2018-09-07 興和株式会社 医薬
EP3603642B1 (en) 2017-03-27 2024-01-10 Alcon Inc. Pharmaceutical preparation
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020172615A1 (en) * 2019-02-22 2020-08-27 Glaukos Corporation Compounds for the treatment of ocular disease
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623228C3 (de) * 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) * 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
DK8386A (da) 1986-01-15 1987-07-09 Tpo Pharmachim Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
JPH01139528A (ja) * 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
ES2075082T3 (es) 1989-03-28 1995-10-01 Nisshin Flour Milling Co Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0630373A1 (en) 1992-03-12 1994-12-28 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6720175B1 (en) 1998-08-18 2004-04-13 The Johns Hopkins University School Of Medicine Nucleic acid molecule encoding homer 1B protein
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000071511A2 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
WO2001037826A1 (en) * 1999-11-26 2001-05-31 Shionogi & Co., Ltd. Npyy5 antagonists
ES2246922T3 (es) 1999-12-28 2006-03-01 Eisai Co., Ltd. Compuestos heterociclicos que tienen grupos de sulfonamida.
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE60141889D1 (de) 2000-02-03 2010-06-02 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AU1401902A (en) 2000-10-17 2002-04-29 Applied Research Systems Pharmaceutically active sulfanilide derivatives
US7163800B2 (en) 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
ES2283543T3 (es) 2001-04-20 2007-11-01 Bayer Pharmaceuticals Corporation Inhibicion de raf kinasa usando quinolil-, isoquinolil- o piridil ureas.
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
WO2003097795A2 (en) 2002-05-13 2003-11-27 Norak Biosciences, Inc. Constitutively translocating cell line
JPWO2004022753A1 (ja) 2002-08-30 2005-12-22 アンジェスＭｇ株式会社 アクチン関連新規細胞骨格タンパク質ｌａｃｓ
CA2502583A1 (en) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AU2004247559B2 (en) 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
JP2005227441A (ja) 2004-02-12 2005-08-25 Konica Minolta Medical & Graphic Inc 光熱写真画像形成材料
JP4857128B2 (ja) 2004-02-20 2012-01-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な化合物
US20080096238A1 (en) 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP2008503492A (ja) 2004-06-17 2008-02-07 スミスクライン・ビーチャム・コーポレイション Ｒｈｏ−キナーゼの新規阻害剤
EP1810965A4 (en) 2004-10-13 2009-10-28 Eisai R&D Man Co Ltd HYDRAZIDE DERIVATIVES
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
GB0425026D0 (en) 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
WO2007060028A1 (en) 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1851197A2 (en) 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
RU2007140957A (ru) 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
US20070135499A1 (en) 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
MX2008008328A (es) 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
JP5476559B2 (ja) 2006-02-10 2014-04-23 国立大学法人九州大学 リン酸化酵素の新規基質ポリペプチド
WO2007100880A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
JP2007246466A (ja) 2006-03-17 2007-09-27 Osaka Univ 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法
JPWO2007142323A1 (ja) 2006-06-08 2009-10-29 宇部興産株式会社 側鎖にスピロ環構造を有する新規インダゾール誘導体
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US20090318485A1 (en) 2006-07-20 2009-12-24 Kalypsys, Inc. Novel inhibitors of rho kinase
WO2008016016A1 (fr) 2006-07-31 2008-02-07 Senju Pharmaceutical Co., Ltd. Préparation liquide aqueuse contenant un amide
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
CA2700988A1 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008049919A2 (en) 2006-10-26 2008-05-02 Devgen N.V. Rho kinase inhibitors
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2008079945A2 (en) 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
CN101595094B (zh) 2006-12-27 2013-02-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮衍生物
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
EP2102164B1 (en) 2006-12-27 2010-12-01 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
BRPI0720710A2 (pt) 2006-12-27 2014-12-23 Sanofi Aventis Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
ATE502027T1 (de) 2006-12-27 2011-04-15 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US20100063282A1 (en) * 2007-04-10 2010-03-11 Boehringer Ingelheim International Gmbh Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) * 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease

Similar Documents

Publication Publication Date Title
US11987589B2 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
US10596145B2 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
US9975868B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
ES2374336T3 (es) Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo.
JP2014502979A5 (enExample)
JP2024522736A (ja) がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
JP2010502564A5 (enExample)
JP2008538741A (ja) 鬱病の治療用及び／又は予防用の医薬組成物
JP2006523216A5 (enExample)
RS60152B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
JP2013516488A (ja) 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療
JP2010529969A5 (enExample)
WO2016101898A1 (zh) 3-[(苯并[d][1，3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
JP2007527417A5 (enExample)
JP6986521B2 (ja) 頭痛の予防的治療のためのカルバメート化合物の使用
JP2025506252A (ja) 鎮痛及び／又は鎮痒機能を有する医薬組成物及びその使用
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
ES2643377T3 (es) Composición farmacéutica para prevenir o tratar degeneración macular
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
JP2023547475A5 (enExample)
MX2008012899A (es) Combinacion de compuestos organicos.
RU2010147881A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
TWI474825B (zh) 治療神經損傷之醫藥套組
CN113015524B (zh) 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途
RU2010120846A (ru) Соединения 2,3-дигидробензофурана, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний